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1. Introduction      
The combination of nanotechnology and medicine has yielded a very promising offspring 
that is bound to bring remarkable advance in fighting cancers. In particular, nanocomposite 
materials based novel nanodevices with bi- or multi- clinical functions appeal more and 
more attention as such nanodevices could realize comprehensive treatment for cancers. 
Because it can provide an effective multimodality approach for fighting cancers, cancer 
comprehensive treatment has been fully acknowledged. Among the broad spectrum of 
nano-biomaterials under investigation for cancer comprehensive treatment, magnetic 
nanocomposite (MNC) materials have gained significant attention due to their unique 
features which not present in other materials. For instance, gene transfection, magnetic 
resonance imaging (MRI), drug delivery, and magnetic mediated hyperthermia can be 
effectively enhanced or realized by the use of magnetic nanoparticles (MNPs) (Shinkai 2004; 
Ito 2005).  Therefore, MNPs are currently believed with the potential to revolutionize the 
current clinical diagnostic and therapeutic techniques. 
In therapeutic oncology, nanothermotherapy is one of the effective approach based on 
MNPs, which can be achieved by applying nanoscaled metallic particles that convert 
electromagnetic energy into heat, for instance, magnetic fluid hyperthermia (MFH) 
mediated by superparamagnetic iron oxide nanoparticles (SPIONs) (Gazeau 2008). Upon 
exposure under alternative magnetic field (AMF), SPIONs can generate heat through 
oscillation of their magnetic moment (Figure 1).Currently, clinical trials at phase II are now 
under investigations for MFH on patients in Germany and Japan and demonstrate very 
inspiring for cancer therapy (Ito 2008). Except for nanothermotherapy, another possible and 
most promising application of MNPs is in drug delivery as carriers for chemotherapeutic 
agents for sustained or controlled delivery for cancer treatment. Compared with the organic 
materials including polymeric nanoparticles, liposomes and micelles under investigation as 
drug delivery nanovectors, the main advantages of MNPs  as drug carriers  summarized by 
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Manuel Arruebo can be: (i) visualized ( SPIONs for MRI); (ii) guided by means of permanent 
magnetic field; and (iii) heated in a magnetic field to trigger drug release and/or combined 
with hyperthermia (Arruebo 2007). These advantages can help to yield an improved 
treatment efficacy and reduction of unwanted side effects. Moreover, it should be particular 
to point that the later capacity of MNPs is of special significance as the hallmarks of 
hyperthermia and its pleotropic effects are in favour of its combined use with chemotherapy 
(Issels, 2008). Therefore, hyperthermia and chemotherapy can be integrated into unique 
formulations or devices through smart engineered MNC materials, which enabling 
simultaneously thermochemotheray for cancer treatment. Herein, followed by a brief 
overview on nanothermotherapy and thermochemotherapy, we will review the design and 
fabrication strategies for the development of MNC devices for thermochemotherapy.   
 
 
Fig. 1. Scheme of magnetic nanothermotherapy mediated by SPIONs 
2. Magnetic nanothermotherapy 
“Quae medicamenta non sanat; ferrum sanat. Quae ferrum non sanat; ignis sanat. Huae vero ignis 
non sanat; insanabilia reportari oportet” (Those diseases which medicines do not cure, the knife 
cures; those which the knife cannot cure, fire cures; and those which fire cannot cure, are to 
be reckoned wholly incurable).   
                                  - Hippocrates of Kos (ca. 460 BC – ca. 370 BC), Western father of medicine 
From aphorism by Hippocrates, he believed that diseases could be cured by raising the 
patient’s body temperature. Although the biological effectiveness of heat in treating cancer has 
been fully recognized for decades, and many of its molecular mechanisms are elucidated, 
however, in oncology clinical hyperthermia is currently regarded as the forth method of 
therapy after surgery, chemotherapy and radiotherapy (Hilderbrandt 2002). Technical 
challenges associated with the currently available hyperthermia modalities can explain the 
seemingly inconsistency, which may include: (i) the difficulty of the uniform heating only 
within the tumor region until the required temperature is reached while without damaging the 
normal tissues nearby, and (ii) the inability to create hyperthermia uniformly throughout the 
tumor volume (Saniei 2009). While the former may bring some unwanted side effect of the 
treatment or unnecessary harm to the patient, the later would leave defective cells unharmed, 
thus resulting in relapse of the tumor. Therefore, the development of novel hyperthermia 
technique capable of specifically targeting tumor tissue and cells is highly desired.  
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Application of nanotechnology has become central focus on cancer treatment and it also 
offers new opportunities and innovative solutions to hyperthermia. The marriage of 
nanotechnology and hyperthermia has yielded nanothermotherapy that is set to bring 
momentous advance in the fight against cancers. As mentioned above, this can be achieved 
by the design of nanometric heating-generating ‘foci’ which can be activated remotely by an 
external AMF (Gazeau 2008). As a completely new approach for targeted cancer treatment, 
nanothermotherapy couples the energy magnetically (through Brownian relaxation or Neel 
relaxation) to nanoparticles only within cancer tissue. In this way, nanothermotherapy aims 
at treating cancer from the cellular or intracellular level, as it is intended the design of 
nanostructured devices capable of penetrating selectively into cancer cells in order to 
generate lethal heating from the cell inside. This process can lead to direct killing of the local 
tumor tissue quickly, specifically and homogeneously, in the meanwhile, 
nanothermotherapy can also effectively activate the immune system to attack distant tumor 
site, a phenomenon known as abscopal effect in cancer treatment. 
The external AMF applied in the treatment belongs to low or middle frequency 
electromagnetic (EM) field. Currently, EM radiation has been considered as a fundamental 
tool in cancer therapy, especially for diagnosis such as MRI and positron emission 
tomography (PET) as it is well accepted that EM fields are not especially contraindicated for 
humans (Goya 2008). The therapeutic potential of EM can be further explored in the 
magnetic nanothermotherapy and the magnetic field applicators at frequencies and field 
values are with full compliance to the safety regulations demanded in clinical applications.  
Safety demand is also the prerequisite criterion for MNPs therefore there is a multitude of 
known MNPs strongly restricted by the demand of non-toxicity and biocompatibility for the 
consideration of  clinical applications.  Normally investigations are focused on magnetic 
iron oxides Fe3O4(magnetite) and γ-Fe2O3(maghemite) which have been proved to be well 
tolerated by the humans.  
Currently, the worldwide first magnetic nanothermotherapy against brain tumors, termed 
as Nano-Cancer® therapy is now under investigation in a phase-II study. Preliminary 
results show evidence of a local effectiveness and with only minor to moderate side effects. 
Besides the clinical trial, In vitro and animal experiments regarding MFH are widely carried 
out worldwide. Table 1 summarizes the major events associated with the development of 
magnetic nanothermotherapy. 
3. Thermochemotherapy: thermal enhancement of drug cytotoxicity 
In clinical, hyperthermia is usually applied as an adjunct treatment to an already established 
treatment modality such as chemotherapy, as hyperthermia can effectively enhance the 
cytotoxicity of various antineoplastic agents (thermal chemosensitization). In several clinical 
phase-III trials, an improvement of both local control and survival rates have been 
demonstrated by adding local/regional hyperthermia to chemotherapy in patients with 
locally advanced or recurrent superficial ad pelvic tumors. Additional application of 
selected chemotherapeutic drugs has been shown to enhance the inhibition of clonogenic 
cell growth at elevated temperatures both in vitro and in animal experiments. Thermal 
enhancement of drug cytotoxicity is accompanied by cellular death and necrosis without 
increasing its oncogenic potential. It also has been recognized that mechanisms for the 
thermal enhancement include increased rate constants of alkylation, increased drug uptake 
and inhibition of repair of drug-induced lethal or sub-lethal damage, etc. Generally, 
 
www.intechopen.com
 Advances in Nanocomposites - Synthesis, Characterization and Industrial Applications s 
 
388 
Time Milestone Events 
1957 
The concept of MMH was initially described by Gilchrist et al (Gilchrist 
1957) 
1959 
MMH with magnetic particles was carried out on rabbits in which inguinal 
lymph modes were successfully targeted with heat (Medal 1959) 
1979 
The concept of intracellular hyperthermia was first proposed by Gondon et 
al (Gondon 1979) 
1993 
Jordan A et al published the first fundamental work describing the real 
potential of magnetic fluids for hyperthermia (Jordan 1993) 
2003~2005 
MagForce Nanotechnology AG carried out the phase I clinical trials of MFH 
in Germany (Hauff-Maier 2007; Johannsen 2007; Wust 2006) 
2005 
MagForce Nanotechnology AG initiated the Phase II clinical trials of MFH 
in Germany 
2008 The concept of Nanothermotherapy was first proposed (Gazeau 2008) 
2009 
The first report of post-mortem neuropathological findings of GBM patients 
undergone MFH was reported (Landeghem 2009) 
2009 Ethical discussion on MFH for brain cancer was published (Muller 2009) 
Table 1. Major events associated with the development of MMH. 
supported by a wealth of biomedical and molecular biological data, the results of clinical 
trials strengthen the current evidence that hyperthermia combined with chemotherapy is an 
effective and practical modality which should be integrated in the present cancer treatment 
armamentarium (Issels 2008). 
4. Design, fabrication and evaluation of magnetic nanocomposite devices for 
thermochemotherapy 
In recognition that MNPs can be acted simultaneously as mediators for magnetic 
nanothermotherapy as well as drug carriers, it is thus highly feasible to design and fabricate 
drug incorporated MNC devices for multimodal cancer treatment of thermochemotherapy, 
to realize the possible thermal enhancement to drug cytotoxicity. As MNPs comprise the ' 
scaffold ‘ of the nanocomposite devices,  we will first address the protocols for the synthesis 
and surface modification of MNPs, and then design and fabrication strategies of the MNC 
devices will be described. 
4.1 Synthesis and surface modification of MNPs  
As mentioned above, iron oxide is the material under close investigation for medical 
application due to its superior biocompatibility with respect to other magnetic materials. 
Apart from biocompatibility, high magnetization, small size (less than 100nm), and narrow 
particle size distribution are also key factors for MNPs to be applied in nanothermatherapy.  
For this purpose, dozens of protocols for SPION synthesis have been developed in recent 
years, including co-precipitation, organic phase synthesis, solvothermal synthesis, etc. The 
simplest, cheapest and most environmentally-friendly procedure by far is based on the co-
precipitation method, which involves the simultaneous precipitation of Fe2+ and Fe3+ in 
basic aqueous media.   
Since the as-synthesized SPIONs in the colloidal form (known as ferrofluid or MF) have a 
large surface area to volume ratio, they are easily to undergo aggregation to form large 
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Fig. 2. TEM images of the Fe3O4 nanoparticles. a: surface modified with oleate sodium; b: 
un-modified nanoparticles 
clusters. Therefore, surface coating or modification is required to improve the properties of 
the MF, such as stability and dispersity. Figure 2(a) illustrates the high-resolution 
transmission electron micrographs (TEM) of Fe3O4 nanoparticles. Due to the large specific 
surface area, high surface enery, and magnetization of the MNPs, the un-modified 
nanoparticles were severely aggregated (Figure 2(b)). However, after surface modification 
by sodium oleate, the nanoparticles are almost mono-dispersed with seldom aggregation. 
Stability of the MF can also be significantly enhanced and the MNPs are able to suspend in 
aqueous environment stably for months after surface modification. Besides, inductive 
heating capacity of MNPs, a vital issue related with nanothermotherapy can be greatly 
promoted by proper modification. Except for physical and chemical properties of the MNPs,  
endocytosis or cell uptake of the MNPs can be optimized and it has been reported that the 
aminosilan coated MNPs would be taken up by prostate carcinoma cells but not by normal 
prostate cells. All the findings strongly suggest surface modification plays critical roles in 
the properties of MNPs and therefore to this end, great attentions have been paid on 
choosing appropriate coating materials for functional modifications of SPIONs and detailed 
information can be referred to the careful reviews (Mornet 2004; Gupta 2005; MCCarthy 
2008; Sun 2008). 
4.2 Magnetic nano-drug by surface modification chemistry for cancer 
thermochemotherapy  
In relation to the multi-therapy modality of thermochemotherapy, the intention for the 
design of nanocomposite devices is to use MNPs as one single tool for the combination of 
hyperthermia and chemotherapy to reach an enhanced therapeutic effect. So far there have 
been developed series protocols on how to engineer the two moieties within a single 
nanoplatform. Magnetic nano-drug by surface modification chemistry represents a kind of 
formulation to conjugate or attach drug molecules to the surface of MNPs. A number of 
physical or chemical approaches have been developed for the conjugation or attachment of 
functional molecules with MNPs surface which can be categorized into covalent linkage and 
physical interactions.  
Physical interactions mainly include electrostatic, hydrophilic/hydrophobic and affinity 
interactions. For some charged drug molecules, electrostatic interactions have particularly 
useful in the assembly of magnetic nano-drugs, for instance, cisplatin-functionalized MNPs. 
Cisplatin belongs to platinum-based chemotherapy drug used to treat various types of 
cancers. It can form irreversible crosslink with bases in the DNA and ultimately triggers 
b 
a 
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apoptosis. It has been approved by US FDA for the treatment of a variety of malignancies 
including testicular, ovarian, bladder, small cell lung, as well as head and neck cancers. To 
fabricate cisplatin magnetic nano-drug, the SPIONs cores were coated by a soluble starch 
derivatives so that particles were negative charged with zeta potential of -41mv, allowing 
electrostatic binding of positively charged aquated cisplatin molecules (molecular structure 
shown in Figure 3). The binding process is rapid with high efficiencies. It was reported the 
prepared cisplatin magnetic nano-drug demonstrated ideal inductive heating property 
under AMF. A temperature increase of 47.3K was observed under AMF within 3 minutes, 
which is adequate for hyperthermia treatment (Kettering 2009). Besides, heating can also 
promote a rapid release of cisplatin from the MNPs. Babincova ever reported that under the 
influence of magnetic heating, almost all the drug could be released after 20min, in contrast 
to the spontaneous release of  cisplatin that was only 20% after this time (Babincova 2008). 
This cisplatin release will be favorable for successful chemotherapeutic activity and should 
increase the therapeutic effect of magnetic heating treatment in medicinal application. In 
vitro cytotoxicity of the combined treatment by the cisplatin magnetic nano-drug has been 
carried out on the treatment of BP6 rat sarcoma cells and the results showed that the 
combination therapy is strongly synergistic.  
                            
Fig. 3. Molecular structure of Cisplatin (left) and aquated cisplatin (right) 
Compared with physical interactions, a much broader spectrum of approaches have been 
developed based on the covalent linkage or chemical coupling strategy. In a most recent 
review paper, Veiseh et al summarized that covalent linkage mainly comprises three 
approaches: direct nanoparticle conjugation, click chemistry and covalent linker chemistry 
(Veiseh 2010). Unique advantages and drawbacks of each of the three approaches were 
addressed in detail. Here, we report the fabrication and characterization of epirubicin-
immobilized magnetic nano-drug that may potentially be applied for thermochemotherapy. 
Epirubicin (molecular structure shown in Figure 4) is an anthracycline drug used for 
chemotherapy, which acts by intercalating DNA strands. Intercalation results in complex 
formation which inhibits DNA and RNA synthesis. It also triggers DNA cleavage by 
topoisomerase II, resulting in mechanisms that lead to cell death. In order to immobilize the 
epirubicin molecules onto the surface of MNPs, conjugation strategy by linker chemistry 
was adopted. Briefly, polyarylic acid (PAA) was applied as the coating material to introduce 
carboxyl groups onto the SPIONs surface. The amino group of epirubicin can be conjugated 
with SPIONs via amide bond by applying the carbodiimides (EDC) and N-
hydroxysuccinimide (NHS or sulfo-NHS) as the chemical linkers. The immobilization 
scheme of the conjugation was illustrated in Figure5. 
Figure 6 demonstrates the shape, size and degree of uniformity of the PAA modified and 
epirubicin immobolized SPIONs. Both SPIONs are spherical in shape, mono-dispersed with 
diameter around 10nm. There is no significant change in size after epirubicin conjugation. X-
ray powder diffraction patterns of epirubicin conjugated SPIONs was shown in Figure 7. 
From the pattern of the sample, it was found that there were a series of characteristic peaks 
at 2.968(220), 2.535(311), 2.103(400), 1.719(422), 1.614(511) and 1.478(440), demonstrating the 
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Fig. 4. Molecular structure of epirubicin 
 
Fig. 5. Immobilization scheme of the conjugation of epirubicin and SPIONs by applying 
EDC/Sulfo-NHS as chemical linkers 
 
   
Fig. 6. Morphology of MNPs by TEM (left: PAA-MNPs; right: EPB-PAA-MNPs) 
patterns were well indexed to the inverse cubic spinel phase of Fe3O4. This suggested that 
conjugation of epirubicin to the SPIONs has no effect on the crystalline structure of the 
SPIONs cores. The VSM measurement of magnetization of the epirubicin-MNPs at 300K is 
also shown in Figure 7. It can be seen from this figure that the MNPs show supermagnetic 
characteristics with zero hysteresis cycle. No coercive field and remnant magnetization can 
be observed. However, the magnetization was remarkably decreased by the conjugation of 
epirubicin onto the SPIONs. 
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Fig. 7. XRD and magnetization curve of  MNPs 
The heating profiles of the epirubicin-MNPs suspensions with different MNPs 
concentrations under AMF of 300kHz were shown in Figure 8. As can be seen in Figure 8, 
higher particle concentration results in a greater increase in the temperature. The desired 
temperature can be achieved by appropriate adjusting the MNPs concentration.  
Effect of heating on the epirubicin release was shown in Figure 9, which clearly 
demonstrated that under the influence of magnetic heating, almost all the drug can be 
released after 48 hour, in contrast to the spontaneous release of epirubicin that was only 50% 
after this time period. In vitro evaluation of the thermochemotherapy mediated by 
epirubicin-MNPs was carried out by the treatment of human gastric cancer SGC-7901.The 
viability data of SGC-7901 cells subjected to mono- treatment by epirubicinl and 
nanothermotherapy, as well as bi-modal treatment by thermochemotherapy are 
summarized in Figure 10. Assessment of viable SGC-7901 cells after various treatments 
showed mono-treatment treatment by hyperthermia or epirubicin released from magnetic 
nano-carrier could cause retarded proliferation on the cells. When the bi-modal treatment 
was applied on the cells, an even significantly greater decrease can be noticed on the cell 
viability (p<0.05), indicating an intensity effect of nanothermotherapy on epirubicin 
treatment. Although in vivo investigation should be carried out for the validation of the 
formulation, the findings we report here strongly support that drug conjugated MNC 
fabricated by covalent linkage is feasible for a combined thermochemotherapy in the cancer 
treatment.  
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Fig. 8. Heating profiles of the epirubicin-MNPs suspensions with different MNPs 
concentrations under AMF of 300kHz 
 
Fig. 9. Effect of heating on the epirubicin release from the EPB-MNPs 
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Fig. 10. Comparison of different treatment modality on the SGC-7901 cell viability  
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4.3 Solar-planet structured magnetic nanocomposite devices for cancer 
thermochemotherapy  
Although surface modification chemistry provides a versatile tool for conjugating the drug 
molecules onto the MNPs surface, there is still some restrictions for this strategy. It was 
suggested by Veiseh et al that the choice of chemistry should be dictated by the chemical 
properties and functional groups found on the SPION coating and ligand to be linked 
(Veiseh 2010).  For most of the drug molecules, there are no proper functional groups nor is 
it convenient to introduce such a functional group onto the MNPs surface for further 
conjugation. Besides, SPIONs applied in nanothermotherapy are normally hydrophilic, 
whilst there are numerous drugs are not soluble in water, therefore it is very challenging to 
find an appropriate medium to carry out the modification chemistry. We thus report here 
so-called solar-planet structured MNC devices for the combined thermochemotherapy. In 
the present study, docetaxel is used as a model small molecule anticancer drug, which is a 
poorly water-soluble, semi-synthetic taxane analog commonly used in the treatment of 
breast cancer,ovarian cancer, small and non-small cell lung cancer, prostate cancer. For the 
purpose of fabricating the solar-planet structured MNC devices, docetaxel loaded polymeric 
nanoparticles (DNPs) composed of carboxylic-terminated poly(D,L-lactic-co-glycolic acid) 
(PLGA) with Vitamin E TPGS as emulsifier for sustained drug release were prepared by a 
modified solvent extraction/evaporation technique. Intensive investigations have been 
carried out for the DNPs and the detailed fabrication protocols of DNPs could be found 
from the published work (Feng 2007). The size of the DNPs fabricated by solvent 
evaporation method is around 200nm. Furthermore, the MNPs modified with amino groups 
could be covalently attached to the surface of carboxylic terminated DNPs to form the so-
called solar (DNPs)-planet (MNPs) structured MNC by EDC/NHS crosslinking protocol as 
illustrated in Figure 5.  
TPGS-emulsified PLGA nanoparticles were found more advantageous than any other kind 
of PLGA nanoparticles in resulting much higher drug EE, cellular uptake, and in vitro cancer 
cell cytotoxicity, and more desirable in vivo pharmacokinetics. The nanoparticles were found 
to be spherical with diameter of 200nm (Figure 11), which are close to the optimum size for 
cellular uptake in vitro. Before carrying out in vitro and in vivo investigations on the novel 
nanocomposite for thermochemotherapy, fluorescent observation was applied to confirm 
the formation of the solar-planet structured MNC. Firstly, docetaxel loaded PLGA NPs were 
labelled with coumarin-6 as the fluorescent marker. After the conjugation of the amino-
coated MNPs and the fluorescent PLGA NPs, the product was collected by the permanent 
magnet and then underwent thorough washing for at least 3 times by DI water. The 
suspension was then subjected for fluorescent observation. It is clearly demonstrated from 
Figure 12 that there is much stronger fluorescent intensity compared with the control group, 
where there was no the linker molecules EDC/NHS during the conjugation. This 
observation strongly confirmed the formation of the so-called solar-planet structured MNC.  
Our in vitro analysis has demonstrated the thermal enhancement on docetaxel cytotoxicity 
can be achieved by the solar-planet structure MNC (data not shown). Further on, this novel 
nanocomposite device was applied in vivo to evaluate the effect of themochemotherapy on 
the tumor bearing nude mice. The temperature for hyperthermia was controlled around 
46°C and the drug was administered at 10mg/kg dose. The time course of C6 tumor nodules 
growth subjected to different treatment was shown in Figure 13, which is obviously 
demonstrated that the tumor volume of the mice in the control group steadily increased 
with no evidence of regression. While both mono-treatment of thermotherapy and  
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Fig. 11. SEM images of docetaxel loaded polymeric nanoparticles 
 
   
Fig. 12. Fluorescent observation of conjugation MNPs with DNPs by covalent linker 
chemistry with (left) and without (right) the application of EDC/NHS as chemical linkers. 
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Fig. 13. Tumor growth of C6 cells in non-treated control mice (n = 10), mice treated with 
nanothermotherapy (n = 10, T=46℃), mice treated with docetaxel (dose=10mg/kg) and mice 
treated with themochemotherapy. Points, mean tumor volume (mm3); bars, SD. 
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chemotherapy can greatly inhibit the in vivo tumor growth, tumor volume in the group of 
bi-modal treatment mediated by the novel MNC was significantly reduced compared with 
chemotherapy (p<0.05) and control group (p<0.001). Our observation supports that solar-
planet structured MNC is a novel and effective mediator for magnetic thermochemotherapy. 
The MNC can realize cancer comprehensive treatment thus has great potential in clinical 
application. 
4.4 Drug loaded magnetic nanocomposite biodegradable implants for cancer 
thermochemotherapy  
Either the magnetic nano-drug or the solar-planet nanocomposite discussed above is in the 
injectable formulation. The particles are dispersed in the aqueous continuous phase (most 
often PBS buffer) to form a stable nanocomposite colloid or suspension. For clinical 
application, the colloid or suspension can be administered by direct injection, arterial 
infusion or intravenous infusion. However, in some cases the injectable formulations may 
result in limited clinical effectiveness, for instance, post-surgical local cancer treatment for 
malignant gliomas. Malignant gliomas such as glioblastoma multiform (GBM) characterized 
by aggressive proliferation of undifferentiated cells, pervasive invasion into distant healthy 
brain tissue and a high penchant to recur is among the most recalcitrant tumors to be 
treated.  Currently, surgical debulking of the accessible tumor from the patient's brain is the 
conventional clinical treatment for glioma. However, the amount of tumor removed is often 
limited by proximity to critical regions for brain function, thus resulting in risk of tumor re-
growth from residual tumor. In clinical, cancer remission can be limited by conventional 
systemic post-surgical treatment and for this purpose, biodegradable controlled release 
polymeric implants could be surgically located at the site of tumor removal during the 
debulking surgery.  
It is well acknowledge that the use of surgically implanted local release systems made of 
biodegradable polymers for drug delivery over extended periods of time has good potential 
in glioma treatment. Gliadel® (polifeprosan 20 with carmustine implant) has been approved 
by the US FDA for use in post-surgical local chemotherapy against recurrent malignant 
glioma. However, despite its potential, clinical trials with commercial Gliadel® wafer 
delivering carmustin vs. Placebo wafers have been shown to small improvements in median 
survivability of patients diagnosed with high-grade malignant gliomas from 11.6 to 13.9 
months, and from 4.6 to 6.4 months for recurrent cases. In response, Ranganath et al have 
explored the controlled release of alternative chemotherapeutic agents (paclitaxel) and 
fadiosensitization (etanidazole) for treatment (Ranganath 2010). Since the advantages for 
comprehensive cancer treatment has been recognized, it is thus highly significant to develop 
composite polymeric surgical implant to achieve multimodality approach for fighting 
cancers. In principle, such kind of treatment can be realized by applying of the tailored 
magnetic nanoparticles (MNPs) composite polymeric film. Fe3O4 MNPs acting as the agent 
for MMH, and anti-cancer drug docetaxel as chemotherapeutic agent were incorporated 
within the biodegradable polymeric film (Zhao 2009). 
Figure 14 gives the observations of the MNC film prepared by the solvent evaporation 
method. Poly (D, L) lactide-trimethylene carbonate (PLA-PTMC) copolymer was employed 
as the film matrix, as its inhibitive effect of adhesion formation after surgery has been 
confirmed. The film is flexible, smooth and homogeneous. Figure 2 also indicated a 
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morphology difference between the nanocomposite film surfaces of air-solvent interface and 
solvent-substrate interface. With the evaporation of the solvent and under the action of 
gravity, the MNPs would be precipitated out and deposited onto the substrate forming a 
rather rigid and homogeneous surface. On the other side, with a higher solubility with 
solvent, PLA-PTMC tends to concentrate at the air-solvent interface and formed an 
immiscible blending/mixture with MNPs clusters, which result in the roughness formation. 
It is worth mentioning that such a rough surface would be more significant for facilitating 
drug release from the polymeric matrix. The heating profiles of the nanocomposite 
polymeric films with different MNPs contents under AMF of 300kHz were shown in Figure 
15. It is obvious to notice that the heating curve exhibits an asymptote, which signals the 
equilibrium of the heating process. The curves show the final temperatures upon 
equilibrium (Te) depend strongly on the MNPs contents, i.e. higher magnetic particles 
content within the film can ensure a higher Te. Another decisive factor for the heating 
process is the magnetic field intensity. As can be seen in Figure 15, higher field intensity   
 
            
Fig. 14. SEM images of nanocomposite films (left: MNPs nanocomposite film(50% MNPs 
loading and 5%docetaxel loading) at solvent-substrate interface; right: same nanocomposite 
film at air-solvent interface) 
  
Fig. 15. Inductive heating profiles of nanocomposite films under AMF at different field 
intensity  (left: with 50% MNPs; right: with 25% MNPs) 
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Fig. 16. In vitro drug release profile of docetaxel (5% drug loading) 
results in a greater increase in the temperature, which means more energy can be generated 
by the MNPs within the films. The desired temperature can be achieved by appropriate 
choosing the MNPs content or adjusting the field intensity. All of these can guarantee the 
temperature requirement for the hyperthermia for cancer treatment. The release profiles of 
docetaxel from the polymeric films in 14 days were investigated and the results are shown 
in Figure 16. In general, the release of docetaxel from the films was characterized by an 
initial rapid release phase followed by a slower release phase. Figure 16 also demonstrates 
20min exposure of the film under AMF would greatly facilitate the docetaxel release from 
the film. This phenomenon may be attributed to the accelerated diffusion of docetaxel from 
the film to the PBS buffer upon heating generated from AMF exposure. 
Both in vitro and in vivo studies have been carried out for the evaluation of the 
biocompatability, cytotoxicity and anti-cancer effectiveness of themochemotherapy 
mediated by the MNC film. Biocompatability of the prepared nanocomposite film has been 
fully confirmed by in vitro and in vivo investigations. Assessment of viable C6 cells after 
various treatments showed treatment by docetaxel released from film could cause retarded 
proliferation on the cells. When the bi-modal treatment by combination of MIH and 
chemotherapy was applied on the C6 cells, an even significantly greater decrease can be 
noticed on the cell viability (p<0.01, data not shown), indicating an intensity effect of MIH 
on docetaxel treatment. The in vivo study was performed tumor bearing nude mice. 
Xenografts of human glioma cell lines would be established by subcutaneous inoculation of 
U251 MG cells into the hind legs of BALB/c nude mice. For animals under placebo and 
experimental groups, a small incision by aseptic surgery was performed on the skin and 
tumor was reached after which 3/4 tumor volume would be carefully excised. The film 
discs would then be implanted well onto the residual tumor bed and subsequently the 
wound would be closed using subcutaneous suturing.  Mice were then exposed under the 
AMF for 30mins treatment and the temperature of the tumor site was about 46°C. The body 
temperature was not affected and the mice did not have symptoms of dehydration and all 
survived the whole experiment of two weeks. Tumors in the thermochemotherapy group 
shrunk most significantly, as compared with those of the control groups and hyperthermia 
treatment only.  
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Fig. 17. The clinical photography of the tumor of mice under different treatment after 10 
days (left: control; middle: hyperthermia (46°C) only and right: Thermochemotherapy by the 
nanocomposite film (46°C, docetaxel dose=10mg/kg).  
5. Conclusion 
In this chapter, various MNC devices for cancer thermochemotherapy are discussed and the 
detailed structures are summarized and illustrated in Figure 18. Except for the above-
mentioned MNC devices, drug encapsulated magnetic cationic liposome (MCL) and 
thermoresponsive core-shell MNPs are also under intensive investigation for the bi-modal 
therapy of combined hyperthermia with chemotherapy (Shinkai 2004; Purushotham 2010). 
The nanocomposite devices exhibit advantageous feature for a facilitated drug delivery 
from the nano-carriers and the magnetic mediated heating potential is adequate for 
hyperthermic treatments. We thus conclude that even though further detailed investigations 
are still necessary, tentative use in local tumor therapies aiming at a specific 
chemotherapeutic release in combination with magnetic heating is promising and feasible in 
the long term.  
 
                
                              a                           b                      c                                 d 
 
              
 
Fig. 18. Illustration of various MNC devices discussed in this chapter (a: Magnetic Nano-
Drug by covalent linkage; b: Magnetic Nano-Drug by electrostatic interaction; c: solar-planet 
structured MNC; d: drug-loaded MNC film) 
It is worth noting for the research and development on MNC devices for cancer 
thermochemotherapy discussed in this chapter, we only focus on the functions of MNPs as 
drug delivery carriers and mediators for MFH. Other features of MNPs, such as MRI 
contrast agent, gene transfection carriers as well as passive targeting driven by permanent 
magnet are not addressed here. Decisive understanding of the properties of MNPs will 
increase their potentials for medical applications, and  the potentials of MNPs as unique 
platform for cancer diagnosis (MRI), nanothermotherapy, chemotherapy as well as gene 
therapy should be further explored to improve the medical techniques for cancer treatment. 
MNPDrug Polymeric nanoparticles Polymeric Film 
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